Skip to main content

Table 1 Overview of Nrf2-interacting factors in cancer cell lines

From: Targeting Nrf2 may reverse the drug resistance in ovarian cancer

Gene

Effects on Nrf2

Effects on cell

Tumor model

Resistance to

References

P62

Activator

Protective

SKOV3/DDP

Cisplatin

[48]

CD99

Activator

Protective

A2780,COC1/DDP

Cisplatin

[50, 51]

ABCF2

Activator

Protective

A2780

Cisplatin

[52]

ATF2

Inhibitor

Cytotoxic

SKOV3

Cisplatin

[53]

AKR1C1

Activator

Protective

Platinum

[54]

SIRT5

Activator

Protective

A2780,SKOV3,CAOV3

Cisplatin

[55]

SLC40A1

Inhibitor

Cytotoxic

A2780CP,PEO4,COC1/DDP

Cisplatin

[56]

HER1

Activator

Protective

PEO1, SKOV3, and OVCAR3

lapatinib and erlotinib

[82]

HER2/HER3

Activator

Protective

PEO4,OVCAR4,SKOV3

Pertuzumab/Trastuzumab/Docetaxel

[80]

ABCG2

Activator

Protective

SKOV3

Mppa-PDT

[89]

GPX4

Activator

Protective

AMC-HN2–11/SNU

Ferroptosis

[92, 93]

CBS

Activator

Protective

SKOV3 and OVCA429

Ferroptosis

[94]

Compounds

 Brusatol

Inhibitor

Cytotoxic

SKOV3/HEC-1-A/A549

[96]

 Ailanthone

Inhibitor

Cytotoxic

A2780/CP70

Cisplatin

[97]

 Ascorbic acid

Inhibitor

Cytotoxic

KCL22/SR; Hela

Imatinib;cisplatin / adriamycin

[98, 99]

 Apigenin

Inhibitor

Cytotoxic

BEL-7402/ADM

Doxorubicin

[100]